Prosecution Insights
Last updated: August 16, 2026
Application No. 17/777,909

METHODS OF ADMINISTERING VOXELOTOR

Final Rejection §102
Filed
May 18, 2022
Priority
Nov 19, 2019 — provisional 62/937,706 +2 more
Examiner
SANCHEZ, JUSTIN CHRISTOPHER
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pfizer Inc.
OA Round
2 (Final)
86%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 86% — above average
86%
Career Allowance Rate
38 granted / 44 resolved
+26.4% vs TC avg
Moderate +15% lift
Without
With
+14.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
36 currently pending
Career history
74
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
32.3%
-7.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
35.4%
-4.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 44 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-15 and 17-24, submitted 27 January 2026, are pending in the application. Claims 17-24 remain withdrawn. Claims 1-15 remain rejected. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Rejections – Maintained The status of the rejections in the previous Office Action are set out below. Rejections under 35 U.S.C. § 103 Applicant asserts that Hutchaleelaha et al. should not be admissible as prior art under 35 U.S.C. 102(a)(1) due to the reference being first published 11 February 2019. Applicant additionally notes that the instant application claims priority to provisional applications 62/940,154, filed on 25 November 2019, and 62/937,706 filed on 19 November 2019. However, the Applicant did not include a statement in the specification at the time of filing and has not provided a declaration to invoke a 102(b)(1)(A) exception. Consequently, the rejections of the previous Office Action are maintained and the pending claims under examination (i.e., claims 1-15) remain rejected. To overcome the rejection, the Applicant could provide a declaration stating that they are invoking a 102(b) exception. See MPEP § 2153.01(a). Conclusion Claims 1-15 remain rejected. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN CHRISTOPHER SANCHEZ whose telephone number is (703)756-5336. The examiner can normally be reached Monday -Friday (0730-1700). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JUSTIN CHRISTOPHER SANCHEZ Examiner Art Unit 1622 /J.C.S./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

May 18, 2022
Application Filed
Jul 28, 2025
Non-Final Rejection mailed — §102
Jan 27, 2026
Response Filed
Mar 26, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12698287
ARYL-FUSED ISOSELENAZOLE COMPOUND CONTAINING TETRAZINE SUBSTITUENT, SYNTHESIS METHOD THEREFOR, AND USE THEREOF
3y 10m to grant Granted Aug 04, 2026
Patent 12691115
METHODS FOR TREATMENT OF OBESITY, ATHEROSCLEROSIS, AND THROMBOSIS
4y 8m to grant Granted Jul 28, 2026
Patent 12685724
IMPROVED ANTIDEPRESSANT THERAPY
3y 11m to grant Granted Jul 21, 2026
Patent 12643882
INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS
3y 0m to grant Granted Jun 02, 2026
Patent 12624039
BTK INHIBITORS
3y 10m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
86%
Grant Probability
99%
With Interview (+14.7%)
3y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 44 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month